Asia stocks edge higher as tech meanders on Nvidia; Hong Kong hit by soft earnings
Protalix BioTherapeutics, Inc. (NYSE American:PLX) entered into an amendment to its at-the-market (ATM) equity offering agreement with H.C. Wainwright & Co., LLC, as announced Friday. The amendment updates the existing sales agreement, originally dated February 27, 2023 and previously amended on March 17, 2025, to reflect the effectiveness of the company’s new registration statement on Form S-3 (Registration No. 333-286802).
Under the amended agreement, Protalix may continue to offer and sell shares of its common stock, $0.001 par value, from time to time through H.C. Wainwright & Co. as its sales agent under the ATM program. The company also filed a legal opinion from Mayer Brown LLP regarding the validity of the shares to be issued under the program.
The information is based on a press release statement included in the company’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Protalix Biotherapeutics (NYSE:PLX) Inc reported its second-quarter 2025 earnings, showcasing a mixed financial performance. The company missed earnings per share (EPS) expectations, reporting a loss of $0.04 per share compared to the anticipated $0.11, resulting in a 136.36% miss. Despite this, Protalix exceeded revenue forecasts by achieving $25.77 million in revenue, surpassing the expected $23.10 million by 11.56%. These developments highlight the company’s ongoing financial challenges and successes. The earnings results have drawn attention from investors and analysts alike. The revenue beat suggests some positive momentum, although the significant EPS miss indicates underlying issues that may need addressing. Analysts and investors will be closely monitoring Protalix’s future performance and strategic decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.